



SAFETY DATA SHEET

Revision date: 05-Nov-2014

Version: 1.0

Page 1 of 12

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)

Trade Name: IBUPIRAC; IBUPROFENE; IBUPROFENO

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Non-steroidal, anti-inflammatory drug (NSAID) antipyretic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
1 Giralda Farms
Madison, NJ 07940

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Other Hazards No data available
Australian Hazard Classification (NOHSC): Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
------------	------------	-----------------------	-------------------	--------------------	---

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 2 of 12
Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ibuprofen	15687-27-1	239-784-6	Repr.Cat3;R62-63 Xn;R22	Acute Tox.4 (H302) Repr.2 (H361fd)	4
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Amaranth	915-67-3	213-022-2	Not Listed	Not Listed	*
Carboxymethylcellulose sodium	9004-32-4	Not Listed	Not Listed	Not Listed	*
Flavor	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	Not Listed	*
Monoammonium glycyrrhizinate	53956-04-0	258-887-7	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	Not Listed	*
Propylparaben	94-13-3	202-307-7	Not Listed	Not Listed	*
Simethicone emulsion	67762-90-7	Not Listed	Not Listed	Not Listed	*
Sodium cyclamate	139-05-9	205-348-9	Not Listed	Not Listed	*
Sodium Lauryl Sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Sodium saccharin	128-44-9	204-886-1	Not Listed	Not Listed	*
Sorbitol solution	50-70-4	200-061-5	Not Listed	Not Listed	*
Water, purified	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 3 of 12
Version: 1.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing dust, vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Ibuprofen

Pfizer OEL TWA-8 Hr: 3000µg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³

Australia TWA 10 mg/m³

Belgium OEL - TWA 10 mg/m³

Estonia OEL - TWA 10 mg/m³

France OEL - TWA 10 mg/m³

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 4 of 12
Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Ireland OEL - TWAs	10 mg/m ³ 4 mg/m ³
Latvia OEL - TWA	2 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³
Vietnam OEL - TWAs	10 mg/m ³ 5 mg/m ³

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Suspension	Color:	Pink
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	No data available.		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 5 of 12
Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Partition Coefficient: (Method, pH, Endpoint, Value)

Polysorbate 80

No data available

Ibuprofen

No data available

Carboxymethylcellulose sodium

No data available

Microcrystalline cellulose

No data available

Sorbitol solution

No data available

Sucrose

No data available

Sodium cyclamate

No data available

Sodium saccharin

No data available

Monoammonium glycyrrhizinate

No data available

Sodium Lauryl Sulfate

No data available

Simethicone emulsion

No data available

Methylparaben

No data available

Propylparaben

No data available

Flavor

No data available

Water, purified

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 6 of 12
Version: 1.0

10. STABILITY AND REACTIVITY

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Short Term:

Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Acute overdose and/or chronic abuse of ibuprofen may cause kidney effects.

Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on developing fetus

Known Clinical Effects:

Adverse effects associated with therapeutic use include gastrointestinal effects such as nausea, pain, heartburn, bleeding, ulceration, and perforation. Drowsiness, fatigue, or headache are also possible. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation.

Acute Toxicity: (Species, Route, End Point, Dose)

Polysorbate 80

Rat Oral LD50 25 g/kg

Ibuprofen

Rat Oral LD 50 1600 mg/kg

Rat Inhalation LC 50 > 20mg/L

Carboxymethylcellulose sodium

Mouse Oral LD50 > 27,000 mg/kg

Rat Oral LD50 27,000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Sorbitol solution

Rat Oral LD50 15,900 mg/kg

Mouse Oral LD50 17,800mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Sodium cyclamate

Rat Oral LD50 1280 mg/kg

Sodium saccharin

Mouse Oral LD50 17.5 g/kg

Rat Oral LD50 14.2 - 17g/kg

SAFETY DATA SHEET

Material Name: **Ibuprofen 40 mg/mL (Oral Suspension)**
Revision date: **05-Nov-2014**

Page 7 of 12
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Rat Intraperitoneal LD50 7100mg/kg

Sodium Lauryl Sulfate

Rat Oral LD 50 1288 mg/kg

Rat Sub-tenon injection (eye) LD 50 210mg/kg

Propylparaben

Mouse Oral LD 50 6332 mg/kg

Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ibuprofen

4 Day(s) Rat Oral 200 mg/kg Gastrointestinal System

30 Day(s) Dog Oral 480 mg/kg Gastrointestinal system

2 Week(s) Rat Oral 1300 mg/kg Liver

Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOAEL Liver, Kidney, Ureter, Bladder

Sodium saccharin

36 Week(s) Rat Oral 756 g/kg LOAEL Kidney, Ureter, Bladder

54 Day(s) Rat Oral 32400 mg/kg LOAEL Immune system

Sodium Lauryl Sulfate

3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system

4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ibuprofen

Fertility and Embryonic Development Rat rectal 100 mg/kg/day Fertility

Fertility and Embryonic Development Rat rectal 200 mg/kg/day Fetotoxicity

Embryo / Fetal Development Rabbit Oral 60 mg/kg/day Not Teratogenic

Embryo / Fetal Development Rat Oral 180 mg/kg/day Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ibuprofen

Bacterial Mutagenicity (Ames) *Salmonella* Negative

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 8 of 12
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Sodium cyclamate

IARC: Group 3 (Not Classifiable)

Sodium saccharin

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided. See aquatic toxicity data for individual components below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ibuprofen

Daphnia magna (Water Flea) EC50 48 Hours 108 mg/L

Desmodesmus subcapitata (Green Alga) EC50 72 Hours 315 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 9 of 12
Version: 1.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

Amaranth

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	213-022-2

Carboxymethylcellulose sodium

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Ibuprofen

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 2 Schedule 3 Schedule 4
EU EINECS/ELINCS List	239-784-6

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 10 of 12
Version: 1.0

15. REGULATORY INFORMATION

Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder
EU EINECS/ELINCS List	232-674-9
 Monoammonium glycyrrhizinate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	258-887-7
 Polysorbate 80	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
 Propylparaben	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-307-7
 Simethicone emulsion	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
 Sodium cyclamate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	205-348-9
 Sodium Lauryl Sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	205-788-1
 Sodium saccharin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 11 of 12
Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	204-886-1
Sorbitol solution	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-061-5
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9
Water, purified	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.2; H361fd - Suspected of damaging fertility. Suspected of damaging the unborn child.

Toxic to Reproduction: Category 3
Xn - Harmful

R22 - Harmful if swallowed.
R62 - Possible risk of impaired fertility.
R63 - Possible risk of harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Revision date: 05-Nov-2014
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

SAFETY DATA SHEET

Material Name: Ibuprofen 40 mg/mL (Oral Suspension)
Revision date: 05-Nov-2014

Page 12 of 12
Version: 1.0

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet